Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

No More Easy Vaccines, Merck's Gerberding Says In Call For Collaboration

This article was originally published in The Pink Sheet Daily

Executive Summary

The easy ones have already been created, she tells BIO, noting there is growing cooperation in pre-competitive activities.

You may also be interested in...



FDA Thinking "Seriously, Deeply" About Range Of Approval Strategies – Hamburg

FDA is considering further “modulations” of its current approaches to drug approvals in order to encourage innovation and get products to market more quickly, Commissioner Margaret Hamburg commented during a panel session at the Biotechnology Industry Organization International Convention in Washington, D.C. on June 28.

FDA Thinking "Seriously, Deeply" About Range Of Approval Strategies – Hamburg

FDA is considering further “modulations” of its current approaches to drug approvals in order to encourage innovation and get products to market more quickly, Commissioner Margaret Hamburg commented during a panel session at the Biotechnology Industry Organization International Convention in Washington, D.C. on June 28.

Selecta/JDRF Collaboration Seeks Vaccine To Prevent Or Treat Type 1 Diabetes

JDRF will provide milestone-based financial support toward preclinical proof of concept for a tolerogenic vaccine candidate.

Topics

UsernamePublicRestriction

Register

LL1125120

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel